Baermed

Baermed is a Swiss-based healthcare and biotechnology group specializing in abdominal medicine, visceral surgery, and regenerative medicine. The company is a pioneer in tissue engineering, focusing on the development of biomedical mini-organs and cell matrix implants to treat chronic diseases. Its lead program, the HEPADUA Mini-Liver Implant, is a patented cell regeneration procedure currently in Phase 2 clinical trials for patients with severe chronic liver cirrhosis. Baermed operates through three main units: Baermed Practice for clinical care, Baermed Research for basic and clinical studies, and Baermed Solutions for the commercialization of its technologies. The group maintains a strong international presence with research facilities in Indonesia and corporate entities in Switzerland and Singapore.